Protara Therapeutics (TARA) Current Leases (2019 - 2026)
Protara Therapeutics (TARA) posted quarterly Current Leases of $1.3 million for Q1 2026, up 8.03% year-over-year from $1.2 million in Q1 2025, and up 1.77% quarter-over-quarter from $1.2 million in Q4 2025.
Protara Therapeutics (TARA) Current Leases (2019 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Current Leases for 8 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 8.03% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 8.03% YoY), while the FY2025 annual figure was $1.2 million, up 10.5% from the prior year.
- Current Leases advanced to $1.3 million in Q1 2026 per TARA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Current Leases topped out at $1.3 million in Q1 2026 and bottomed at $870000.0 in Q1 2022.
- Historically, Current Leases has averaged $1.0 million across 5 years, with a median of $1.0 million in 2024.
- On a YoY basis, Current Leases climbed as much as 845.65% in 2022 and fell as far as 7.14% in 2022.
- Protara Therapeutics' Current Leases stood at $917000.0 in 2022, then grew by 7.2% to $983000.0 in 2023, then increased by 14.34% to $1.1 million in 2024, then rose by 10.5% to $1.2 million in 2025, then grew by 1.77% to $1.3 million in 2026.
- Business Quant data shows TARA's Current Leases at $1.3 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Mn |
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | 983,000.00 |
| Sep 30, 2023 | 966,000.00 |
| Jun 30, 2023 | 949,000.00 |
| Mar 31, 2023 | 933,000.00 |
| Dec 31, 2022 | 917,000.00 |
| Sep 30, 2022 | 901,000.00 |
| Jun 30, 2022 | 885,000.00 |
| Mar 31, 2022 | 870,000.00 |
| Dec 31, 2021 | 855,000.00 |
| Sep 30, 2021 | 840,000.00 |